Linked Life Data

20032282

Source:http://linkedlifedata.com/resource/pubmed/id/20032282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-3-1
pubmed:abstractText
OBJECTIVE We studied the C-peptide response to oral glucose with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS Among 504 DPT-1 participants <15 years of age, longitudinal analyses were performed in 36 progressors and 80 nonprogressors. Progressors had oral glucose tolerance tests (OGTTs) at baseline and every 6 months from 2.0 to 0.5 years before diagnosis; nonprogressors had OGTTs over similar intervals before their last visit. Sixty-six progressors and 192 nonprogressors were also studied proximal to and at diagnosis. RESULTS The 30-0 min C-peptide difference from OGTTs performed 2.0 years before diagnosis in progressors was lower than the 30-0 min C-peptide difference from OGTTs performed 2.0 years before the last visit in nonprogressors (P < 0.01) and remained lower over time. The 90-60 min C-peptide difference was positive at every OGTT before diagnosis in progressors, whereas it was negative at every OGTT before the last visit in nonprogressors (P < 0.01 at 2.0 years). The percentage whose peak C-peptide occurred at 120 min was higher in progressors at 2.0 years (P < 0.05); this persisted over time (P < 0.001 at 0.5 years). However, the peak C-peptide levels were only significantly lower at 0.5 years in progressors (P < 0.01). The timing of the peak C-peptide predicted type 1 diabetes (P < 0.001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-12021118, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-12037147, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-15855569, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-16306337, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-16505520, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-17192330, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-17616634, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-18650369, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-5216975, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-6061732, http://linkedlifedata.com/resource/pubmed/commentcorrection/20032282-7713313
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1935-5548
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
620-5
pubmed:dateRevised
2011-7-25
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
pubmed:affiliation
Division of Endocrinology, University of Miami, Miami, Florida, USA. jsosenko@med.miami.edu
pubmed:publicationType
Journal Article